Table 1 Patient characteristics
From: Ex-vivo RNA expression analysis of vaccine candidate genes in COPD sputum samples
All participants N = 127 | Selected N = 69 | |
|---|---|---|
Age at enrolment (years) mean ± SD | 66.8 ± 8.6 | 66.3 ± 8.8 |
Female sex, n (%) | 59 (46.5%) | 25 (36.2%) |
Smoking history (pack-years), median (IQR) | 47.0 (33.7–60.0) | NA |
Medication for COPD, n (%) | 127 (100%) | NA |
Influenza vaccination during previous year, n (%) | 114 (89.8%) | NA |
Pneumococcal vaccination during previous year, n (%) | 12 (9.4%) | NA |
COPD severity status at enrolment, n (%) | ||
Mild | 0 (0%) | 0 (0%) |
Moderate | 57 (44.9%) | 34 (49.3%) |
Severe | 51 (40.2%) | 27 (39.1%) |
Very severe | 19 (15.0%) | 8 (11.6%) |
Number of patients reporting exacerbations in preceding 12 months, n (%) | ||
One exacerbation | 28 (22.0%) | 14 (20.3%) |
Two exacerbations | 37 (29.1%) | 16 (23.2%) |
Three exacerbations | 25 (19.7%) | 16 (23.2%) |
Four or more exacerbations | 37 (29.1%) | 23 (33.3%) |
Number of exacerbations in preceding 12 months, mean ± SD and median (IQR) | 3.1 ± 2.3 and 2 (2–4) | 3.5 ± 2.7 and 3 (2–5) |